| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
CAMP4 Therapeutics Corporation
13D/A
CAMP · 13463J101
|
9.9% |
8/31/2026
Event 8/27/2026
|
||||
| 5AM Ventures VI, L.P. | 3.2% | |||||
| 5AM Partners VI, LLC | 3.2% | |||||
| 5AM Ventures VII, L.P. | 6.3% | |||||
| 5AM Partners VII, LLC | 6.3% | |||||
| 5AM Opportunities II, L.P. | 0.5% | |||||
| 5AM Opportunities II (GP), LLC | 0.5% | |||||
| Andrew J. Schwab | 9.9% | |||||
| Kush Parmar | 9.9% | |||||
|
Vor Biopharma Inc.
13D/A
VOR · 929033108
|
3.5% |
7/9/2025
Event 7/8/2025
|
||||
| 5AM Ventures VI, L.P. | 2.6% | |||||
| 5AM Partners VI, LLC | 2.6% | |||||
| 5AM Opportunities I, L.P. | 1.0% | |||||
| 5AM Opportunities I (GP), LLC | 1.0% | |||||
| Andrew J. Schwab | 3.5% | |||||
| Kush Parmar | 3.5% | |||||
| Schedule 13G · 1 security · passive | ||||||
|
Artiva Biotherapeutics, Inc.
13G/A
ARTV · 04317A107
|
4.8% |
8/10/2026
Event 6/30/2026
|
||||
| 5AM Ventures VI, L.P. | 2.4% | |||||
| 5AM Partners VI, LLC | 2.4% | |||||
| 5AM Opportunities II, L.P. | 2.4% | |||||
| 5AM Opportunities II (GP), LLC | 2.4% | |||||
| Andrew J. Schwab | 4.8% | |||||
| Kush Parmar | 4.8% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.